Clinically, these PARP inhibitors have been mainly applied for the maintenance therapy of malignancies or the treatment for recurrent cancer, and the combination therapies with other kind of inhibitors also show great potential for the overcome of tumor resistance (Rose et al., 2020; Tung and Garber, 2022). Here, PARP1 is linked to neoplasm.